8 results about "Regulatory molecules" patented technology

The invention discloses an application of glycosylated phosphatidylinositol specific phospholipase D1 (GPLD1) as a sperm-egg recognition and / or binding regulation molecule.

The technology described herein is directed to Aptamer and Ribozyme Equilibrium Shifting (ARES) regions, including ON-switches and OFF-switches, which can be harnessed to regulate the stability of RNA molecules. Also described herein are compositions comprising such RNA molecules and methods of using them to regulate translation of cargo polypeptides.

The application discloses a kind of big steric hindrance C-C coupling palladium ligand and synthesis method, ligand is used naphthyl as the main group of stable ligand, this group provides big plane rigid configuration during ligand use, simultaneously, it provides big π electron for complex molecule to stabilize complex;In addition, the configuration of pyridofuran is used, the N coordination point of traditional N-P bidentate ligand is introduced O by furan this functional group in ortho position to adjust the chemical environment of intramolecular N coordination point, so as to modify the traditional N-P bidentate ligand to tridentate ligand, this change can effectively increase the penetration ability of Pd active center in actual ligand use to improve catalytic activity.

The invention discloses a benzothiazole non-condensed ring A-D-A '-D-A type organic solar cell acceptor material and a preparation method and application thereof, a benzothiazole unit is used as a central nuclear electron withdrawing unit (A-unit), and then the benzothiazole unit, the central nuclear electron withdrawing unit (A-unit), an electron donating unit (D-unit) and a terminal group are synthesized into the organic solar cell acceptor material with an A-D-A'-D-A structure. Wherein benzothiazole as an asymmetric central core structure can enhance the dipole moment of molecules, optimize the accumulation among the molecules and improve the blending property of a donor and an acceptor, and the characteristics can jointly promote charge transfer to inhibit the bimolecular recombination condition. The molecular morphology is regulated and controlled by connecting different structural groups to a top branched chain, and meanwhile, different atoms can be introduced into a benzene ring to regulate and control the chemical energy level. In addition, the polymer also has the characteristics that the aggregation behavior and the light absorption range of molecules can be adjusted by accessing different terminal groups. The benzothiazole-based non-fused ring A-D-A '-D-A type acceptor material provided by the invention is few in synthesis and preparation steps, simple in purification process and high in yield.

This invention discloses the application of the CEMIP-ITGA5 axis as a target in the preparation of products that regulate epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma, belonging to the fields of tumor molecular biology and precision medicine. Through TCGA-LUAD cohort bioinformatics analysis, immunohistochemical verification of clinical specimens, cell function experiments, and a nude mouse subcutaneous xenograft model, this invention discovers and confirms that the CEMIP-ITGA5 axis participates in regulating epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma. Specifically, CEMIP positively regulates ITGA5 expression, thereby promoting EMT, proliferation, migration, invasion, and in vivo tumorigenesis in lung adenocarcinoma cells. Based on this, the present invention provides two applications: Firstly, by detecting the expression levels of the dual genes CEMIP and ITGA5, a kit for assessing the risk of epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma can be prepared. The combined detection of CEMIP and ITGA5 can reflect the activation status of the CEMIP-ITGA5 axis at both the upstream regulatory molecule and downstream effector molecule levels, providing auxiliary molecular evidence for assessing EMT and metastasis-related risks in lung adenocarcinoma. Secondly, by targeting and inhibiting the expression or function of CEMIP and / or ITGA5, drugs can be prepared to inhibit epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma, effectively reversing the epithelial-mesenchymal transition phenotype and inhibiting tumor malignant progression. This invention provides novel molecular targets and technical solutions independent of known signaling pathways for prognostic assessment and targeted therapy of lung adenocarcinoma.

The present application relates to a kind of target protein conformation targeting regulatory molecules and regulatory methods in living cells.The protein conformation targeting regulatory molecules include: 1) with the targeting group of selectively binding target protein as skeleton, 2) two active functional groups are modified on the skeleton, c) rigid connecting arm introduced between targeting group and active functional group.Based on the above characteristics, after the protein conformation targeting regulatory molecules of the cell are incubated with cell, they are rapidly combined with target protein in cell specifically through cell membrane, and covalent reaction occurs with amino acid near binding pocket, to target the conformation of target protein is regulated.According to the difference of protein conformation and reaction site, different active groups and rigid connecting arm are used, to realize the accurate regulation of target protein conformation in different functional states.The present application provides important technical support in the field of exploring protein conformation and function, expanding the library of druggable proteins, researching new use of old drugs, disease treatment or prevention.

The invention relates to the technical field of gene editing, in particular to an accurate and efficient DNA-free gene editing method. According to the gene editing method, a nucleic acid editing composition is adopted to perform gene editing on an organism; the nucleic acid editing composition comprises a first sgRNA, a second sgRNA, helicase and a DNA damage repair regulating molecule, the first sgRNA and the second sgRNA are used for causing preset mutation; the helicase comprises one or more of DDX17, BLM or UPF1, and the helicase comprises one or more of the DDX17, the BLM and the UPF1; and the DNA damage repairing and regulating molecule is LY294002. According to the gene editing method provided by the invention, accurate and efficient mutation of the gene can be realized through the specific nucleic acid editing composition, so that gene editing groups of the same type can be rapidly created, and the gene editing method has important application value.

The invention discloses a detection method for promoting lung cancer drug resistance through glutamine metabolism of macrophages, and belongs to the field of tumor biology and medical detection.The method comprises the steps that a sample to be detected is obtained and is a biological sample related to lung cancer; separating and purifying macrophages from the sample to be detected; detecting related indexes of glutamine metabolism of the macrophages, wherein the related indexes of glutamine metabolism comprise the content of glutamine and the expression level of a glutamine synthesis key enzyme GLS2; glutamine metabolism of macrophages in a tumor microenvironment and osimertinib drug resistance of lung cancer are combined for detection, and the defect that immunometabolism is neglected in traditional detection is overcome; multiple dimensions of'metabolic index-drug resistance index-molecular mechanism-intervention verification 'are covered, detection indexes comprise glutamine content, key enzyme, regulation molecules and lung cancer cell function / animal model phenotype, and the result is more reliable.